This website is for UK Healthcare Professionals only

ASH 2021 and BSH 2022.

About the latest data for VENCLYXTO® in Chronic Lymphocytic Leukaemia (CLL)

To receive the latest AbbVie information on upcoming congresses


On demand: Access content from ASH 2021

Dr Toby Eyre and Dr Piers Patten

Insights from ASH 2021:
Chronic Lymphocytic Leukaemia

Dr Piers Patten and Dr Toby Eyre review the findings of CLL-13, CLL-14 and MURANO studies

On demand: Access content from BSH 2022

Dr Toby Eyre and Dr Othman Al-Sawaf

Haematological Conundrums: Fixed treatment duration vs. continuous therapy in CLL

The case for continuous treatment - Dr Toby Eyre
The case for fixed treatment duration - Dr Othman Al-Sawaf

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCCLL-220175. Date of preparation: May 2022.